Adverse Drug Reaction Gender Differences in Patients Treated with REGEN-COV (Casirivimab/Imdevimab) for Treatment of COVID-19
Full text | Download pdf
Danell Haines, PhD Research Consultant; Ryan Garst, PharmD, MBA, IgCP, BCSCP, NHIA
NHIF retrospectively collected and analyzed data from the REGEN-COV patient charts. Data analysis showed that home infused REGENCOV achieved comparable outcomes to other sites of care and provided improved access to treatment.